Le Lézard
Classified in: Health
Subject: PLW

Vivera Enters $6B Market with Speech Assessment and Feedback Device Patent Allowance

NEWPORT BEACH, Calif., Oct. 25, 2022 /PRNewswire/ -- Vivera is pleased to announce that the U.S. Patent and Trademark Office (USPTO) has issued a U.S. patent allowance for the Company's Speech Fluency Evaluation and Feedback method and device.

"The Company is committed to developing devices and technologies to assist the entire health sector." -Paul Edalat

Stuttering, a speech disorder characterized by speech disfluencies, affects 70 million patients worldwide. While there is no cure for stuttering, there are treatment options available. However, it can be challenging for clinicians to assess stuttering as the severity of a person's stuttering often varies over time and between situations and settings.

Vivera realized that for patients to receive the most effective treatment and care, clinicians needed a more accurate way to evaluate patient speech disfluencies in real-world environments. In response, the Company developed the stuttering severity assessment device.

This device will allow for continuous monitoring of a patient's stuttering to give a more accurate assessment and provide feedback to the patient who stutters. The personalized patient information collected will allow clinicians the ability to monitor the therapeutic effects of treatment and adjust each patient's therapy accordingly.

"The symptoms of stuttering have long been known to vary situation by situation and day by day, raising challenges for those living with stuttering and the clinicians working to help them," said Gerald A. Maguire, M.D., D.L.F.A.P.A., Vivera's Chief Neurosciences Advisor. "The promise of the device is that clinicians and patients alike will be able to have an accurate assessment of stuttering over time and will be able to then optimize treatment."

"This device will enable stuttering assessments to be done in real-world settings," said Mehdi Hatamian, Ph.D., Vivera's Chief Scientific Advisor. He continued, "The device will provide metrics to measure each patient while also monitoring the efficacy of medications and other therapies. Ultimately, clinicians will be able to work better with patients to tailor treatments to their needs. It can also be a valuable tool for clinical studies for stuttering drugs."

The stuttering assessment and feedback device will include at least one processor configured to collect audio data, extract environment and speech information, and analyze that data. The device is designed to evaluate and measure speech events based on the analysis of the data.

"Vivera continues to be disruptive in the medical device space," said Stephen J. McColgan, M.D., M.B.A., Vivera's Chief Medical Officer. "This device will assess speech patterns and help optimize treatment."

"Vivera is excited about this recent patent allowance," said Paul Edalat, Chairman and CEO of Vivera. "The Company is committed to developing devices and technologies to assist the entire health sector and is always focused on putting patients first."

About Vivera Pharmaceuticals

Vivera Pharmaceuticals is an innovative, science-driven pharmaceutical company located in Southern California. The Company has global exclusivity to license the patented and patent-pending TABMELT  sublingual drug delivery system for pharmaceutical use and holds its own issued patents on ZICOH, a smart dose-controlled electronic medical device. The Company has also received a Notice of Allowance for its portable telemedicine station, MDZone. With multiple divisions, including its pharmaceutical, neurosciences, medical technology, biosciences, and advanced diagnostics divisions, Vivera Pharmaceuticals is vertically integrated with patented technology, manufacturing capabilities, and distribution for its products.

For more information, please visit viverapharmaceuticals.com or connect with us on LinkedInFacebookTwitter, or Instagram.

Ashley LeVine
[email protected]

SOURCE Vivera Pharmaceuticals, Inc.

These press releases may also interest you

at 21:15
The National Health IT Collaborative for the Underserved (NHIT), the first and oldest national non-profit focused on equitable access to health technology for underserved communities and communities of color, celebrated its 15th anniversary today...

at 21:00
The "Social Anxiety Disorder (SAD) - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The Social Anxiety Disorder (SAD) market report provides current treatment practices, emerging...

at 20:45
The "Global Continuous Glucose Monitoring Solutions Market, 2027 Forecast" report has been added to  ResearchAndMarkets.com's offering. Technological advancements and strategic partnerships create new opportunities for CGM vendors. The rising...

at 20:40
Researchers at Kanazawa University report in ACS Nano how ultrathin layers of tin disulfide can be used to accelerate the chemical reduction of carbon dioxide - a finding that is highly relevant for our quest towards a carbon-neutral society....

at 20:15
The "Regenerative Medicines: Bone and Joint Applications" report has been added to  ResearchAndMarkets.com's offering. The global market for regenerative medicine for bone and joint applications was valued at $9.6 billion in 2022. By technology, this...

at 20:10
The Canadian Animal Health Institute is thrilled to announce the winners of the inaugural ?Cutest Pets on Parliament Hill Contest'. Parliamentarians, Senators, staffers, and members of the Press Gallery on Parliament Hill, submitted more than 65...

News published on and distributed by: